This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Age 20-85
ASA score 1-3 or ECOG Performance Status of 0 to 2
Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and/or tumor biopsy
Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer
Patients who participate in another interventional study
Patients with known allergy to one or more of the study medications, or to any medication from the non-steroidal anti-inflammatory drug group or beta-blockers family
Patients treated chronically with any type of a beta-adrenergic blocker or a COX inhibitor, except use of Aspirin, which will be discontinued at least 7 days prior to surgery, and until 3 weeks post-surgery
Patients currently suffering from asthma (אסתמה פעילה בלבד), or required hospital admission or change in medical treatment for asthma within the past year
Tel-Aviv Sourasky Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
The Chaim Sheba Medical Center
Collaborator